NASDAQ:VXRTVaxart Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vaxart Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.22 +2.24 (+28.07 %) (As of 07/13/2020 01:12 PM ET) Add Compare Share Today's Range$8.56Now: $10.22▼$11.0450-Day Range$2.26MA: $4.15▼$8.8752-Week Range$0.25Now: $10.22▼$14.30Volume67.43 million shsAverage Volume38.60 million shsMarket Capitalization$758.12 millionP/E RatioN/ADividend YieldN/ABeta0.31 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.67, Vaxart has a potential upside of 11.7% from its current price of $10.44.Amount of Analyst CoverageVaxart has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesVaxart has received 266 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVaxart has received 276 “underperform” votes. (Add your “underperform” vote.)Community SentimentVaxart has received 50.92% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote “Outperform” if you believe VXRT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $289,795,963.00 in company stock.Percentage Held by Insiders36.70% of the stock of Vaxart is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.98% of the stock of Vaxart is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaxart are expected to decrease in the coming year, from ($0.19) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -12.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -12.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 38.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webwww.vaxart.com Phone650-550-3500Debt Debt-to-Equity Ratio0.04 Current Ratio4.52 Quick Ratio4.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.86 million Price / Sales76.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book37.85Profitability EPS (Most Recent Fiscal Year)($0.86) Net Income$-18,650,000.00 Net Margins-252.86% Return on Equity-94.20% Return on Assets-43.89%Miscellaneous Employees34 Outstanding Shares74,180,000Market Cap$758.12 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:VXRT Rates by TradingView Receive VXRT News and Ratings via Email Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Vaxart (NASDAQ:VXRT) Frequently Asked Questions How has Vaxart's stock been impacted by COVID-19 (Coronavirus)? Vaxart's stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VXRT stock has increased by 404.3% and is now trading at $10.44. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Vaxart? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaxart. When is Vaxart's next earnings date? Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Vaxart. How were Vaxart's earnings last quarter? Vaxart Inc (NASDAQ:VXRT) posted its quarterly earnings results on Tuesday, May, 12th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.04) by $0.02. The biotechnology company earned $2.90 million during the quarter, compared to the consensus estimate of $2.80 million. Vaxart had a negative net margin of 252.86% and a negative return on equity of 94.20%. View Vaxart's earnings history. When did Vaxart's stock split? How did Vaxart's stock split work? Shares of Vaxart reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split. What price target have analysts set for VXRT? 3 brokers have issued 12-month price objectives for Vaxart's shares. Their forecasts range from $6.00 to $22.00. On average, they expect Vaxart's stock price to reach $11.67 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price. View analysts' price targets for Vaxart. Has Vaxart been receiving favorable news coverage? News articles about VXRT stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vaxart earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Vaxart. Who are some of Vaxart's key competitors? Some companies that are related to Vaxart include Twist Bioscience (TWST), Immunovant (IMVT), Alector (ALEC), Editas Medicine (EDIT), Bill.com (RVMD), Forma Therapeutics (FMTX), Sorrento Therapeutics (SRNE), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Mesoblast (MESO), Legend Biotech (PCVX), Regenxbio (RGNX), Beam Therapeutics (BEAM) and Nantkwest (NK). View all competitors. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), VBI Vaccines (VBIV), Conatus Pharmaceuticals (CNAT), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), Agile Therapeutics (AGRX) and Co-Diagnostics (CODX). Who are Vaxart's key executives? Vaxart's management team includes the following people: Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO, CFO & Director (Age 61)Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)Mr. John M. Harland M.B.A., CPA, Consultant (Age 67)Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 60)Mr. Brant Biehn, Sr. VP of Commercial Operations What is Vaxart's stock symbol? Vaxart trades on the NASDAQ under the ticker symbol "VXRT." How do I buy shares of Vaxart? Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vaxart's stock price today? One share of VXRT stock can currently be purchased for approximately $10.44. How big of a company is Vaxart? Vaxart has a market capitalization of $774.44 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe. What is Vaxart's official website? The official website for Vaxart is www.vaxart.com. How can I contact Vaxart? Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
